At this conference, Dr. Yin Xiushan from RocRock Biotech shared the latest research findings, clinical trial data, and positive attempts of cell therapy in chronic diseases and anti-aging fields, as well as the development progress of integrated cell preparation and treatment devices. He discussed with international peers on how to improve the safety, efficacy, and accessibility of cell therapy. He also shared the milestone news that RocRock Biotech's leading pipeline RR-M01 successfully entered the IIT clinical research phase in 2023, with 2 patients having been dosed and 2 patients screened and enrolled, and the subjects showing stable vital signs and strong comfort after the treatment, further validating the safety and efficacy of the RR-M01 cell injection.

RocRock Biotech upholds an open and inclusive spirit in scientific research and highly values international exchange and cooperation, widely communicating research results with international peers to jointly promote the innovation and progress of cell therapy technology. During the discussion, experts and scholars brainstormed and discussed cutting-edge issues in the field of cell therapy. After in-depth discussions and evaluations, RocRock Biotech launched strategic cooperation with multiple parties to promote the innovation and progress of CAR-M cell therapy technology from transcriptomics, translatomics, proteomics, and other multidisciplinary approaches. All parties will work together to contribute to global health endeavors. RocRock Biotech looks forward to establishing deeper cooperative relationships with more international peers, and continues to be dedicated to promoting the research and application of CAR-M cell therapy, providing safer and more effective treatment options for patients with solid tumors, improving patients' quality of life, and extending their survival.